Diagnosis and treatment

Connecticut head coach Geno Auriemma reacts during the second half of an NCAA college basketball game against DePaul on Monday, Dec. 16, 2019 in Chicago, Ill. (AP Photo/Matt Marton)
December 17, 2019 - 1:56 pm
STORRS, Conn. (AP) — UConn coach Geno Auriemma is scheduled to undergo minor surgery Wednesday that could keep him off the court for the Huskies' game this weekend against Oklahoma. The school says the 65-year-old Hall-of-Famer will undergo a procedure to relieve symptoms of diverticulitis, a...
Read More
FILE - In this July 10, 2019, file photo, President Donald Trump speaks during an event on kidney health at the Ronald Reagan Building and International Trade Center in Washington. The U.S. government proposed new rules Tuesday, Dec. 17, to increase organ transplants. The proposals come after Trump in July ordered a revamping of the nation's care for kidney disease that included spurring more transplants of kidneys and other organs. (AP Photo/Evan Vucci, File)
December 17, 2019 - 9:19 am
WASHINGTON (AP) — The U.S. government proposed new rules Tuesday to increase organ transplants — steps to make it easier for the living to donate and to make sure that organs from the deceased don't go to waste. The proposals come after President Donald Trump in July ordered a revamping of the...
Read More
December 17, 2019 - 9:05 am
WASHINGTON (AP) — The U.S. government proposed new rules Tuesday to increase organ transplants — steps to make it easier for the living to donate and to make sure that organs from the deceased don't go to waste. The proposals come after President Donald Trump in July ordered a revamping of the...
Read More
December 16, 2019 - 5:45 am
BALTIMORE (AP) — A Baltimore man is suing over a take-home paternity test he says incorrectly indicated he was the father of a 1-year-old girl. Nnanaka Nwofor wants the Ohio company that conducted the DNA test to pay $75,000 for the cost of supporting the child and her mother and the pain of...
Read More
This Dec. 12, 2019, photo shows a sign at the Mundipharma International headquarters at Cambridge Science Park in England. Mundipharma is the international affiliate of Purdue Pharma, the maker of the blockbuster painkiller OxyContin. Mundipharma is now marketing Nyxoid, a new brand of naloxone, an opioid overdose reversal medication. (AP Photo/Leila Coker)
December 15, 2019 - 10:06 pm
The gleaming white booth towered over the medical conference in Italy in October, advertising a new brand of antidote for opioid overdoses. “Be prepared. Get naloxone. Save a life,” the slogan on its walls said. Some conference attendees were stunned when they saw the company logo: Mundipharma, the...
Read More
This Dec. 12, 2019, photo shows a sign at the Mundipharma International headquarters at Cambridge Science Park in England. Mundipharma is the international affiliate of Purdue Pharma, the maker of the blockbuster painkiller OxyContin. Mundipharma is now marketing Nyxoid, a new brand of naloxone, an opioid overdose reversal medication. (AP Photo/Leila Coker)
December 15, 2019 - 3:22 pm
The gleaming white booth towered over the medical conference in Italy in October, advertising a new brand of antidote for opioid overdoses. “Be prepared. Get naloxone. Save a life,” the slogan on its walls said. Some conference attendees were stunned when they saw the company logo: Mundipharma, the...
Read More
This undated image provided by Dr. Andrew Kolodny shows Purdue Pharma’s international affiliate, Mundipharma, promoting Nyxoid, a new brand of opioid overdose reversal medication, at a medical conference in Italy. The photo was taken by Kolodny, a frequent critic of Purdue Pharma who has testified against the company. (Andrew Kolodny via AP)
December 15, 2019 - 12:56 am
The gleaming white booth towered over the medical conference in Italy in October, advertising a new brand of antidote for opioid overdoses. “Be prepared. Get naloxone. Save a life,” the slogan on its walls said. Some conference attendees were stunned when they saw the company logo: Mundipharma, the...
Read More
This undated photo provided by Amarin in November 2018 shows a capsule of the purified, prescription fish oil Vascepa. On Friday, Dec. 13, 2019, U.S. regulators approved expanded use of the medication for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. (Amarin via AP)
December 13, 2019 - 5:56 pm
TRENTON, N.J. (AP) — U.S. regulators on Friday approved expanded use of a fish oil-based drug for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. Vascepa was approved years ago for people with sky-high triglycerides, a type of fat in blood...
Read More
This undated photo provided by Amarin in November 2018 shows a capsule of the purified, prescription fish oil Vascepa. On Friday, Dec. 13, 2019, U.S. regulators approved expanded use of the medication for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. (Amarin via AP)
December 13, 2019 - 5:53 pm
TRENTON, N.J. (AP) — U.S. regulators on Friday approved expanded use of a fish oil-based drug for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. Vascepa was approved years ago for people with sky-high triglycerides, a type of fat in blood...
Read More
December 13, 2019 - 5:35 pm
TRENTON, N.J. (AP) — U.S. regulators on Friday approved expanded use of a fish oil-based drug for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. Vascepa was approved years ago for people with sky-high triglycerides, a type of fat in blood...
Read More

Pages